BACKGROUND: Pelvic radiation disease (PRD) also widely known as "radiation proctopathy" is a well recognised late side-effect following conventional prostate radiotherapy.
However, endoscopic evaluation and/or specialist referral for new or persistent post-prostate radiotherapy bowel symptoms is not routine and serious diagnoses may potentially be missed. Here we report a policy of endoscopic evaluation of bowel symptoms persisting >90days post radiotherapy for prostate cancer.
METHODS AND MATERIALS: A consecutive series of 102 patients who had radical prostate intensity-modulated radiotherapy (IMRT)/image-guided radiotherapy (IGRT) and who had new or ongoing bowel symptoms or positive faecal occult blood tests (FOBT) on follow up visits more than three months after treatment, were referred for endoscopic examination. All but one (99%) had full colonoscopic investigation.
RESULTS: Endoscopic findings included gastric/colonic/rectal polyps (56%), diverticular disease (49%), haemorrhoids (38%), radiation proctopathy (29%), gastritis/oesophagitis (8%) and rarer diagnoses, including bowel cancer which was found in 3%. Only four patients (4%) had radiation proctopathy without associated pathology and 65 patients (63%) had more than one diagnosis. If flexible sigmoidoscopy alone were used, 36.6% of patients and 46.6% patients with polyp(s) would have had their diagnoses missed.
CONCLUSIONS: Our study has shown that bowel symptoms following prostate IMRT/IGRT are due to numerous diagnoses other than PRD, including malignancy. Routine referral pathways should be developed for endoscopic evaluation/specialist review for patients with new or persistent bowel symptoms (or positive FOBT) following prostate radiotherapy. This recommendation should be considered for incorporation into national guidelines.
Written by:
Min M, Chua B, Guttner Y, Abraham N, Aherne NJ, Hoffmann M, McKay MJ, Shakespeare TP. Are you the author?
North Coast Cancer Institute, Coffs Harbour, Australia; Coffs Harbour Hospital, Australia; North Coast Cancer Institute, Port Macquarie, Australia; North Coast Cancer Institute, Lismore, Australia. ;
Reference: Radiother Oncol. 2014 Jan 8. pii: S0167-8140(13)00629-4.
doi: 10.1016/j.radonc.2013.11.012
PubMed Abstract
PMID: 24412017
UroToday.com Prostate Cancer Section
